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ReviewMitochondria are being recognized as key factors in
many unexpected areas of biomedical science. In addi-
tion to their well-known roles in oxidative phosphory-
lation and metabolism, it is now clear that mitochondria
are also central to cell death, neoplasia, cell differentia-
tion, the innate immune system, oxygen and hypoxia
sensing, and calcium metabolism. Disruption to these
processes contributes to a range of human pathologies,
making mitochondria a potentially important, but
currently seemingly neglected, therapeutic target. Mito-
chondrial dysfunction is often associated with oxidative
damage, calcium dyshomeostasis, defective ATP syn-
thesis, or induction of the permeability transition pore.
Consequently, therapies designed to prevent these
types of damage are beneficial and can be used to treat
many diverse and apparently unrelated indications. Here
we outline the biological properties that make mito-
chondria important determinants of health and disease,
and describe the pharmacological strategies being de-
veloped to address mitochondrial dysfunction.
The many roles of mitochondria
Mitochondria contribute to much of core human metabo-
lism, including oxidative phosphorylation, the tricarboxylic
acid (TCA) cycle, fatty acid oxidation, iron sulfur center and
heme biosynthesis, and amino acid metabolism [1–4] (Box 1,
Figure 1). Mitochondria are also central to apoptotic cell
death and modulate calcium fluxes throughout the cell [1,5].
Superoxide is a reactive oxygen species (ROS) produced by
mitochondria, and it underlies redox signaling in hypoxia
sensing, cell differentiation and innate immunity [6–8].
Mitochondrial function depends on their assembly,
maintenance and dynamics. Mitochondria have their
own DNA (mtDNA) that encodes 37 genes necessary for
assembly of the oxidative phosphorylation machinery [1];
however, most of the 1500 other mitochondrial proteins
are encoded by nuclear genes, translated in the cytoplasm
and then imported into mitochondria [9] (Figure 1). This
dual origin of mitochondrial proteins requires coordination
of the nuclear and mitochondrial genomes, and also many
other cofactors, metals and phospholipids have to be
imported into mitochondria. The organelles move around
the cell coordinated by the cytoskeleton, and also continu-
ally undergo fission and fusion, which is intimately linkedCorresponding author: Murphy, M.P. (mpm@mrc-mbu.cam.ac.uk).
0165-6147/$ – see front matter  2012 Elsevier Ltd. All rights reserved. doi:10.1016/j.tips.2012.to apoptosis, and the removal of dysfunctional mitochondria
[10,11]. Damaged macromolecules within mitochondria are
degraded by specialized intramitochondrial enzymes, and
irreparably disrupted mitochondria are themselves degrad-
ed by generalized autophagy or more targeted mitophagy
[10–12]. Mitochondrial biogenesis and turnover is regulated
and coordinated by multiple transcription factors and tran-
scriptional coactivators, notably peroxisome proliferator-
activated receptor-g coactivator-1a (PGC-1a), that enable
mitochondria to respond to long-term alterations in meta-
bolic demand [13]. Mitochondrial function is integrated
closely into that of the rest of the cell; for example, mito-
chondria are preferentially located in areas of high local ATP
demand. The short-term regulation of electron supply to the
respiratory chain occurs by feedback pathways to upstream
dehydrogenases that also respond to hormones, growth
factors and neuronal stimulation via kinase cascades and
changes in calcium concentration [5]. Mitochondrial oxida-
tive phosphorylation is particularly sensitive to ATP de-
mand through respiratory control, the rapid stimulation of
respiratory chain activity in response to the lowering of the
proton motive force caused by increased ATP synthesis [14]
(Figure 1).
Disruption to mitochondrial assembly, turnover and
function contributes to many disparate pathologies, raising
the need for therapies [1,2,15,16]. Here we outline the issues
and opportunities that arise in considering mitochondria as
a therapeutic target for small molecule interventions. We
focus on the general principles of mitochondrial pharmacol-
ogy, illustrated with a few key examples that demonstrate
the potential and the challenges of targeting mitochondria
through pharmacological intervention.
Primary and secondary mitochondrial dysfunction
Mitochondrial disruption can be divided into two types:
primary or secondary dysfunction. The primary category is
characterized by a mutation to a gene encoded by mtDNA
or a nuclear-encoded gene for a mitochondrial protein, or
from a mitochondrial toxin. An example is Mitochondrial
Encephalopathy Lactic Acidosis and Stroke-like episodes
(MELAS) which is due to a mutation at np 3243 in the
mitochondrial tRNAleu(UUR) gene that leads to the defective
assembly of oxidative phosphorylation complexes and con-
sequent defects in energy metabolism in neuromuscular
systems [17]. Mutations to nuclear genes encoding mito-
chondrial proteins also lead to a wide range of primary03.010 Trends in Pharmacological Sciences, June 2012, Vol. 33, No. 6 341
Box 1. The mitochondrial respiratory chain and oxidative phosphorylation
The central role of mitochondria is the synthesis of ATP by oxidative
phosphorylation. This is carried out by a series of five large, multi-
subunit complexes (I–V) illustrated in Figure I below. Oxidative
Phosphorylation is made up of from 4 to 45 polypeptides that are
embedded in the mitochondrial inner membrane. All these complexes
except complex II are composed of subunits encoded by both the
mitochondrial and nuclear genomes, the latter subsequently im-
ported into mitochondria. The respiratory chain (complexes I–IV)
channels electrons derived from food to oxygen, using the energy
released to make ATP. For this various transporters exist in the
mitochondrial inner membrane that transfer carbohydrates and fatty
acids into the mitochondrial matrix for the first stage of their
oxidation. Electrons from carbohydrates oxidized by the tricarboxylic
acid (TCA) cycle and from fatty acids broken down by b-oxidation
accumulate on the reduced electron carrier NADH. This NADH is
oxidized to NAD+ at complex I (NADH:ubiquinone oxidoreductase)
and the electrons are passed to the CoEnzyme Q (CoQ) pool, a
lipophilic electron carrier existing as oxidized ubiquinone (Q) and
reduced ubiquinol (QH2). The energy released at complex I is used to
pump protons across the mitochondrial inner membrane. Electrons
from the TCA cycle are also passed via succinate to the CoQ pool
through complex II (succinate:ubiquinone oxidoreductase), which
does not pump protons. Similarly, b-oxidation also leads to the
accumulation of electrons on flavoproteins that are also shuttled
to the inner membrane by electron transfer flavoprotein (ETF),
which then passes the electrons to the CoQ pool by the action of
electron transfer flavoprotein:ubiquinone oxidoreductase (ETF:Q
oxidoreductase). The electrons in the CoQ pool are then passed
through complex III (ubiquinol:cytochrome c oxidoreductase) to
cytochrome c and from cytochrome c the electrons are then finally
used to reduce oxygen to water at complex IV (cytochrome c oxidase).
At both complexes III and IV the redox energy is used to pump protons
and charge across the inner membrane. The proton motive force
generated across the inner membrane comprises a membrane
potential (Dcm) of up to approximately 160 mV and a pH gradient of
approximately half a pH unit, equivalent to 30 mV of proton motive
force. The high proton motive force is used to make ATP from ADP and
phosphate (Pi) by the flow of protons back through the FoF1–ATP
synthase (complex V). The ATP is then exported from the mitochon-
drion to the cytoplasm in exchange for cytoplasmic ADP by the adenine
nucleotide translocase (ANT), whereas the phosphate is replaced by
transport from the cytoplasm via the phosphate carrier. The image is
derived from two previous diagrams developed by Professor John E.
Walker and Dr Martin King. Images of 3D structures and electron
density maps are based on an image from Professor John E. Walker
and were generated using PyMOL (DeLano, www.pymol.org) by Dr
Martin King. Complex I is the low resolution structure of the enzyme
from Thermus thermophilus (PDB accession code: 3M9S) to 4.5 A˚ [81].
Complexes III (PDB: 1BE3) and IV (PDB: 1OCC) are the high resolution
structures of the bovine enzymes [82,83]; complex II (PDB: 1ZOY) is the
porcine enzyme [84]. Cytochrome c (PDB: 1CXA) is from Rhodobacter
sphaeroides [85]. ATP synthase (PDB: 2CLY) is a model from Professor
John E. Walker’s group [86]. The mitochondrial ANT (PDB: 1OKC) in
complex with carboxyatractyloside is also shown [87].
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Figure 1. Mitochondrial function and biogenesis. Some of the many roles of mitochondria in cell function and aspects of mitochondrial biogenesis are illustrated. A major
role for mitochondria is the production of ATP through oxidative phosphorylation. Initially, glucose is broken down to pyruvate by glycolysis in the cytosol. Porin channels,
also known as voltage-dependent anion channels (VDACs), enable small molecules to pass through the outer membrane. Activation of AMP-dependent kinase (AMPK)
allows the cell to respond to a low cytosolic ATP/ADP ratio through changes in AMP, and acts on various targets, such as the transcriptional coactivator PGC-1a.
Mitochondrial DNA (mtDNA) encodes 37 genes that are involved in the synthesis of the respiratory chain and the ATP synthase. Additional proteins are imported through
TIM and TOM, translocases of the inner and outer membranes that transport nuclear-encoded proteins into mitochondria. The adenine nucleotide translocase (ANT)
enables the mitochondrion to import ADP and export ATP. Mitochondria also contribute to calcium signaling by taking up calcium into the mitochondrial matrix through the
calcium uniporter (CaU) in response to changes in cytosolic calcium. In addition, mitochondria play a crucial role in apoptosis. When apoptotic signals occur, the outer
membrane becomes compromised and the mitochondrion experiences mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c
(cyt c) and many other pro-apoptotic proteins (not shown) from the intermembrane space into the cytosol where they activate apoptotic cell death.
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6mitochondrial defects [18–20] such as a neonatal defect in
energy metabolism due to mutation of a nuclear gene that
encodes NDUFAF3, an assembly factor for respiratory
complex I [21,22]. In addition, mutations to nuclear-
encoded mitochondrial genes can disrupt many aspects
of mitochondria other than oxidative phosphorylation
including assembly, dynamics and metabolic function
[18–20].
By contrast, secondary mitochondrial dysfunction is
caused by pathological events that originate outside mito-
chondria. For example, in ischemia/reperfusion (I/R) injury,
the initiating event is the interruption and subsequent
reflow of blood supply to the tissue, which leads to extensive
secondary mitochondrial disruption and consequent tissue
damage [16,23]. Other disorders in which secondary mito-
chondrial damage plays a significant role include sepsis,
neurodegeneration, metabolic syndrome, organ transplan-
tation, cancer, autoimmune diseases and diabetes [1,24].Consequently, mitochondria are an important node for
therapeutic intervention, even if damage to the actual or-
ganelle is not the initial pathological event [24].
Diseases due to primary mitochondrial dysfunction are
generally thought of as rare. However, with improved
diagnosis it is now evident that mtDNA mutation can
cause disease in as many as 1 in 5000 of the general
population [25]. The cumulative prevalence of disorders
due to primary mitochondrial dysfunction is not known, in
part because of the diversity in their clinical presentations,
and many more of these are likely to be discovered [18–20].
By contrast, many of the disorders that involve secondary
mitochondrial dysfunction, including cardiac damage in
I/R injury, metabolic syndrome, diabetic complications and
neurodegenerative diseases, are among the most signifi-
cant disorders of developed societies. Thus, there is an
unmet need to treat mitochondrial dysfunction in both
primary and secondary pathologies, with the treatment343
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6of secondary mitochondrial disorders having the potential
to impact on many significant and common conditions.
Correcting primary mitochondrial disorders is particu-
larly challenging. One exception is coenzyme Q (CoQ)
deficiency due to a defect in CoQ biosynthesis, in which
supplying dietary CoQ ameliorates the disease [26]. How-
ever, in most cases, an effective treatment or cure is likely
to require replacement or suppression of the defective
gene, which may be feasible for nuclear genes, but the
prospect of effective gene therapies for mtDNA diseases
remains distant [27]. Thus, most pharmacological inter-
ventions in this area aim to ameliorate the consequences of
the primary defect [26] rather than address the cause of the
malfunction. The therapeutic situation is different for the
many diseases involving secondary mitochondrial dysfunc-
tion, where treatments are not designed to affect mito-
chondria directly. This may give a disheartening picture,
suggesting that mitochondria are an unpromising thera-
peutic target as distinct pharmaceuticals would be re-
quired for each disease. Fortunately this is not the case,
because there are common patterns of cell disruption in
both primary and secondary mitochondrial diseases, de-
spite their disparate causes. Mitochondrial pharmacology
is feasible because therapies that impact on a few commonCytoplasm
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Figure 2. Mitochondrial dysfunction. Disruption to mitochondrial function can be caused
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344damaging pathways can treat patients with a wide range of
primary and secondary mitochondrial disorders.
There are three aspects of mitochondrial damage that
commonly contribute to primary and secondary mitochon-
drial pathologies: oxidative damage, calcium dyshomeo-
stasis and disruption to ATP synthesis (Figure 2). The
mitochondrial respiratory chain (Box 1) is a major source
of superoxide that, in turn, forms hydrogen peroxide and
other damaging ROS [6]. Superoxide production increases
in many pathological scenarios, and mitochondria are
particularly vulnerable to oxidative damage because the
organelle contains several iron sulfur centers, a large
expanse of inner membrane containing unsaturated fatty
acids and densely packed proteins and mtDNA molecules
that are essential to mitochondrial function, all of which
are susceptible to reaction with ROS derived from super-
oxide. Oxidative damage to mitochondria disrupts the
function of the organelle making cell death more probable,
thereby contributing to diverse pathologies such as sepsis,
organ deterioration in transplantation, I/R injury, diabetic
complications and also neurodegenerative diseases [1,6].
Mitochondrial ATP synthesis is frequently disrupted by
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 by primary events, such as mutation to mitochondrial or nuclear genes. Secondary
 often common factors to mitochondrial dysfunction such as increased oxidative
equently, these occur together or lead into each other. The combination of elevated
l permeability transition pore (mPT), which further disrupts mitochondrial function.
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6death and dysfunction [1]. Defective mitochondrial ATP
supply also leads to calcium dyshomeostasis by disrupting
calcium ATPase activity in the endoplasmic/sarcoplasmic
reticulum and in the plasma membrane, allowing cytosolic
calcium levels to rise above the normal signaling range
(1–2 mM) [5]. The uptake of calcium into mitochondria
through the calcium uniporter is responsive to increases
in cytosolic calcium, perhaps to protect against transient
increase in cellular calcium, but sustained calcium eleva-
tion leads to chronic, damaging calcium accumulation
within mitochondria. Oxidative damage, defective ATP
synthesis and calcium dyshomeostasis frequently occur
together, and as each type of damage leads to the other
two, then a vicious cycle is established (Figure 2). Finally,
mitochondrial oxidative damage, ATP depletion and calci-
um overload together induce the mitochondrial permeabil-
ity transition (mPT) [28]. This phenomenon arises due to
the formation of an inner membrane pore that causes
swelling and disruption to mitochondrial function [28].
The physiological role of the mPT and the composition of
the pore are uncertain. However, it is clear that it contrib-
utes to many pathologies such as I/R injury, and that its
formation requires activity of cyclophilin D, a matrix pep-
tidyl prolyl cis-trans isomerase [28].
This toxic constellation of oxidative damage, calcium
dyshomeostasis, disrupted ATP synthesis and induction of
the mPT occurs in many primary and secondary mitochon-
drial disorders. Consequently, therapeutic interventions to
ameliorate these processes are applicable to many differ-
ent indications. This is contrary to the usual drug devel-
opment model where a well-defined protein target that is
linked to a single indication can be modulated precisely by
a selectively bound small molecule. Our view is that suc-
cessfully intervening therapeutically in general damaging
processes is essential for mitochondrial pharmacology to
reach its full potential.
Strategies for mitochondrial pharmacology
There are three strategies for mitochondrial pharmacology
(Figure 3) [4,15]. The first is to make molecules that
selectively accumulate within mitochondria. The second
is to use molecules that bind targets within mitochondria
which rely on the target’s location to effect specificity. The
final approach is to modulate processes outside mitochon-
dria that ultimately alter mitochondrial function.
Targeting bioactive molecules to mitochondria
Lipophilic cations and mitochondria-targeted peptides
have both been developed to target drugs and bioactive
molecules to mitochondria in vivo (Figure 3) [4,29]. These
strategies lead to a dramatically higher concentration of
the targeted compound within mitochondria, greatly in-
creasing potency and enabling less of the compound to be
used, thus minimizing the extramitochondrial metabolism
that can lead to inactivation, excretion or toxic side effects.
These delivery strategies also enable molecules that are
poorly taken up by mitochondria for various reasons (e.g.
hydrophobicity) to be directed to mitochondria in vivo. One
limitation is that these procedures typically involve che-
micals which tend to localize to the mitochondrial matrix
and the matrix-facing surface of the inner membrane.There are many important processes that take place on
the outer surface of the inner membrane, the intermem-
brane space and the outer membrane of mitochondria, but,
as yet, there are no generic strategies to target these
compartments. Another limitation is that currently these
approaches are not organ-specific and the compounds gen-
erally accumulate preferentially in tissues with high
mitochondrial content.
Lipophilic cations such as triphenylphosphonium (TPP)
derivatives are rapidly and extensively taken up by mito-
chondria in vivo driven by the large mitochondrial mem-
brane potential [Dcm (negative inside)] [4]. The mechanism
of uptake is well understood and occurs by the movement of
lipophilic cations through the plasma and mitochondrial
inner membranes due to the extensive hydrophobic surface
area and the large ionic radius of the cation that effectively
lowers the activation energy for membrane passage. The
Nernst equation adequately describes the membrane po-
tential-dependent uptake of lipophilic cations, which
increases 10-fold for every 60 mV of Dcm, leading to their
several hundred-fold uptake within mitochondria in vivo
[30,31] (Figure 3). The use of lipophilic cations to facilitate
the delivery of attached ‘cargo’ within cells was first dem-
onstrated with the lipophilic cation rhodamine 123 which
forms a complex with the anticancer drug cis-platin [32].
Since then, the covalent attachment of the TPP lipophilic
cation has become established as a generic and robust
method to target small, bioactive and probe molecules to
mitochondria in vivo [4].
Peptides can also be used to direct molecules to mito-
chondria, with the Szeto–Schiller (SS) peptides [29] and
the mitochondrial-penetrating peptides (MPPs) [33] prov-
ing the most useful to date. Both classes of peptides
comprise a mix of cationic and hydrophobic alkyl or aro-
matic amino acid residues that are taken up by mitochon-
dria in cells and can be used to deliver attached cargoes
[29,33]. The mechanism of peptide uptake by mitochondria
is less clear than that for TPP species. Results obtained
with MPPs suggest that charge and hydrophobicity deter-
mine accumulation in the mitochondrial matrix [34], al-
though it is not yet established whether passage of MPPs
through the phospholipid bilayer is unmediated and up-
take into mitochondria is simply determined by the Dcm.
By contrast, the uptake of SS peptides is thought to be
independent of Dcm and to rely on selective binding to the
inner membrane; however, the details of how this occurs
and the nature of the putative binding sites are unclear
[29]. More work is required on the biophysical mechanism
of uptake for the two types of peptide, although our view is
that uptake is likely to be by the same general mechanism
in each case.
The major therapeutic use of lipophilic cations and
mitochondria-targeted peptides to date has been to deliver
covalently attached, bioactive cargo to mitochondria [4,29].
This has proven to be a robust approach, and some of the
molecules utilized are shown in Table 1. A variant of this
approach is to design a molecule so that the targeting
module is cleaved from the bioactive moiety within the
mitochondria, releasing the active molecule in the mito-
chondrial matrix (Figure 3). Recent examples of this in-
clude the delivery of lipoic acid, temporarily attached to a345
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Figure 3. Three general strategies to intervene pharmacologically in mitochondrial dysfunction. The first is by targeting compounds to mitochondria. This can be done by
conjugation to a lipophilic cation such as TPP leading to the selective uptake of the attached bioactive moiety or pharmacophore (X) into the mitochondrial matrix.
Alternatively, peptides such as the SS or MPP peptides can also be used. These mitochondria-targeted compounds can act within the mitochondria, or the active
pharmacophore can be released from the targeting moiety within the mitochondrion. Secondly, compounds which are not targeted to mitochondria but which act there by
binding to specific targets can be used. Finally, many compounds can influence mitochondrial dysfunction by affecting processes outside mitochondria, such as the activity
of kinases, transcription factors or transcriptional coactivators.
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6TPP by an enzyme-cleavable ester linkage [35], and the
release of nitric oxide (NO) within mitochondria on reduc-
tion of MitoSNO [36]. A further manifestation of this
approach is to use TPP connected to a bioactive moiety
by a photocleavable linker that can be photolyzed in situ,
thereby delivering the active agent within mitochondria in
a particular tissue or cell. This has been demonstrated in
cells for TPP connected to the uncoupler, 2,4 dinitrophenol
(DNP) by a photolabile linker which releases DNP within346mitochondria upon irradiation [37]. The mitochondrion can
also be used as an intracellular reaction chamber, with two
mitochondria-targeted compounds reacting together to
form a novel product [38], or to generate a bioactive mole-
cule within the mitochondria that can then diffuse out of
the organelle to improve the efficacy or duration of its
action on extramitochondrial targets [36] (Figure 3). Final-
ly, mitochondria-targeting can also be used to enhance the
therapeutic window of a known drug by sequestering active
Table 1. Selected mitochondria-targeted therapeutic compoundsa
In vivo
Compound Mode of action Indications
MitoQ Antioxidant Cardiac I/R injury [4,49]; toxin-induced parkinsonism [42]; endothelial
nitroglycerin tolerance [4,49]; hypertension [4,49]; sepsis [4,49];
adriamycin toxicity [4,49]; kidney damage in type I diabetes [4,49]; kidney
preservation ex vivo [44]; cocaine toxicity [4,49]; alcoholic fatty liver
disease [88]; fatty liver disease [31,89]; liver inflammation in hepatitis C
virus patients [41]
SS31 Antioxidant I/R injury [29]; neuroprotection [29]; insulin resistance [29];
immobilization-induced muscle atrophy [29]; skeletal muscle
burn injury [90]
MitoTempo Antioxidant Hypertension [91]
MitoSNO S-Nitrosation Cardiac IR injury [36,46]
TP187 Mitochondrial toxin Cancer [50]
In vitro
Compound Target
MitoCsA Mitochondrial permeability transition [92]
RevMitoLipoic acid Cleavable delivery of lipoic acid
within mitochondria [35]
MitoPeroxidase Catalytic peroxidase mimetic [93]
MitoCP Antioxidant [94]
MitoVES Anticancer toxin [95]
MitoPorphyrin Photodynamic therapy in cancer [96]
MitoPhotoDNP Light-activated delivery of uncoupler
to mitochondria [37]
aOnly a representative sample of mitochondria-targeted compounds is listed here. See [4] for a more complete listing.
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6compound within the organelle to minimize toxicity at sites
elsewhere in the cell [39].
Both of these mitochondria-targeting strategies have
been shown to work in vivo. Extensive work on mitochon-
dria-targeted TPP compounds has shown that they can be
delivered to mitochondria in vivo following oral adminis-
tration in drinking water [31] or by tablet [40,41], by
intraperitoneal (IP) [42] or intravenous (IV) [30] injection,
by eye drops [43] and into organs ex vivo by infusion [36,44].
TPP compounds have been given safely long-term to sev-
eral rodent models [31,45]. Importantly, they have also
been given orally to patients in Phase II studies for up to 1
year with no safety concerns [40,41]. TPP compounds can
be delivered very rapidly to mitochondria within organs
such as the heart within a few minutes following IV injec-
tion [30], enabling the rapid treatment of acute mitochon-
drial dysfunction [46]. The uptake of TPP compounds is not
uniform across different organs, and although TPP com-
pounds cross the blood–brain barrier (BBB) in sufficient
amounts to protect the brain from degeneration in various
disease models [42,45], the uptake is less than that for
other organs [31]. Studies to date have shown that the
metabolism of TPP compounds is mainly through reaction
of the ‘cargo’ component, with the TPP function remaining
unmodified, and the compounds being excreted in the bile
and in the urine [47].
Experience with peptide delivery systems in vivo is less
extensive, with work to date having only been carried out
on the SS peptides [29]. It has been established that these
can be safely delivered in vivo by subcutaneous, IV and IP
administration [29] leading to tissue uptake. However, the
uptake into mitochondria in vivo has been inferred indi-
rectly from in vitro studies and from the observation of
protection against mitochondrial damage.The major therapeutic application of mitochondria-tar-
geted therapies so far has been as antioxidants to block
mitochondrial oxidative damage [4,29]. Conventional,
untargeted antioxidants have had poor efficacy in clinical
trials [48], and this is in part because they do not accumulate
particularly in mitochondria – the site of much of the
pathological oxidative damage. The observed several hun-
dred-fold accumulation within mitochondria of the mito-
chondria-targeted antioxidants renders them far more
effective in protecting against oxidative damage. The most
extensively investigated mitochondria-targeted antioxidant
to date has been the TPP-modified ubiquinone, MitoQ,
which has shown efficacy in a wide range of animal models
of disorders and has also been taken through to human
studies [49] (Table 1). The unique properties of lipophilic
cations mean that on oral or IV administration MitoQ is very
rapidly taken up from the circulation into cells by direct
movement through the plasma membrane, and this accu-
mulation is driven by the plasma membrane potential [30].
Within the cytosol, the large Dcm leads to the further uptake
of the MitoQ into the mitochondrial matrix, and the extent of
this uptake can be several hundred-fold. Within the mito-
chondria, MitoQ is predominantly adsorbed to the matrix-
facing surface of the inner membrane, facilitating its ability
to protect the components of the membrane involved in
oxidative phosphorylation. The ubiquinone form of MitoQ
is rapidly reduced by respiratory complex II to the ubiquinol
form, which is a very effective chain-breaking antioxidant
that inhibits mitochondrial lipid peroxidation and directly
reacts with oxidants such as peroxynitrite. In carrying out
these reactions, the ubiquinol is converted to a ubisemiqui-
none radical that dismutates to a ubiquinol and a ubiqui-
none, which is then reduced back to a ubiquinol by the
respiratory chain. The ubiquinone form of MitoQ can also347
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6react directly with superoxide. It is the combination of rapid
targeted and extensive uptake with antioxidant efficacy and
rapid recycling back to the active form that makes MitoQ
and related compounds uniquely effective antioxidants. A
range of mitochondria-targeted antioxidants incorporating
the TPP function have been developed including targeted
versions of nitroxide, nitrones, plastoquinones and tocoph-
erol, which have also shown efficacy in many animal models
(Table 1). The SS peptide, SS31, which has an inherent
antioxidant moiety, has also been shown to be effective in
multiple animal models and is now being applied to human
studies [29]. The broad efficacy of mitochondria-targeted
antioxidants strongly supports the concept that mitochon-
drial oxidative damage constitutes an important therapeu-
tic target.
Other types of mitochondria-targeted therapies have
been developed. For example, the increase in Dcm in cancer
cells has led to the development of various mitochondria-
targeted toxins designed to accumulate in these mitochon-
dria and thereby selectively kill cancer cells [50,51] (Table
1). The delivery strategies can also be used to target other
bioactive components or pharmacophores to mitochondria
(Table 1). Although several possibilities are being explored
in vitro, only a few have established in vivo applications to
date. A recent in vivo example is the mitochondria-targeted
S-nitrosating agent MitoSNO [36], which induced the S-
nitrosation of complex I that protects mitochondria and the
heart in vivo from I/R injury [36,46].
Thus, the targeting to mitochondria of bioactives and
pharmacophores is an established and robust procedure
that can greatly expand options for designing compounds
to treat mitochondrial damage in patients, and is a central
platform for the future development of mitochondrial phar-
macology.
Modulating druggable mitochondrial targets and
processes
Mitochondria contain many targets and processes specific
to the organelle that can be modulated by drugs and
bioactive agents. Among these are agents that act as
conventional drugs by binding to and affecting specific
protein targets within mitochondria. A good example is
cyclosporin A (CsA) which acts as an immunosuppressant
and is also an effective inhibitor of cyclophilin D within
mitochondria, thereby preventing the mPT [28]. The in-
duction of the mPT in animal models of I/R injury is caused
by elevated oxidative damage, ATP depletion and calcium
dyshomeostasis, which in combination lead to the cyclo-
philin D-dependent induction of a pore in the mitochondri-
al inner membrane. Once formed, the pore causes
mitochondrial swelling and disrupts ATP synthesis lead-
ing to the necrotic cell death that is a major factor in I/R
injury. By binding to and inhibiting cyclophilin D, CsA can
prevent the induction of the mPT. CsA is licensed as an
immunosuppressant and it was utilized in a pilot human
trial to test whether blocking the mPT could be therapeutic
after myocardial infarction [52]. For this, CsA was admin-
istered to patients intravenously immediately before coro-
nary angioplasty and a decrease in the area of infarcted
tissue was noted in these cases [52]. CsA was also effective
in two related degenerative syndromes called Bethlem348myopathy and Ullrich congenital muscular dystrophy that
are due to mutations in the collagen VI gene [53,54].
Surprisingly, mutations in this extracellular protein lead
to increased mitochondrial dysfunction and cell death in
mouse models, and these defects could be ameliorated with
CsA, suggesting that induction of the mPT was central to
the muscle cell death underlying the pathology [54–56].
These observations engendered an open-label pilot trial on
five patients with collagen VI myopathies where oral
treatment with CsA for a month significantly improved
mitochondrial and cell function as assessed in muscle
biopsies [57]. Inhibitors of cyclophilin D are a very promis-
ing example of how druggable targets in mitochondria can
be modulated. Mitochondria-specific variants of CsA that
do not bind to the cyclophilins found outside the mitochon-
dria are being developed to avoid the immunosuppressant
and toxic side effects of long-term CsA [58].
Another interesting potential mitochondrial target for
pharmacological intervention is the intrinsic pathway of
apoptotic cell death [51]. This can be accessed in several
ways, but one promising target is the key step of mitochon-
drial outer membrane permeabilization (MOMP), during
which rupture of the outer membrane releases proteins
such as cytochrome c (cyt c) from the intermembrane space
and thereby commits the cell to apoptosis [51]. Although
the nature of MOMP itself is still unclear, it involves
interplay between antiapoptotic proteins such as B Cell
Lymphoma protein-2 (BCL-2) and related pro-apoptotic
proteins such as BCL-2 homologous antagonist/killer
(BAK) [51]. Activation of pro-apoptotic proteins, such as
BAK, leads to the formation of a pore in the mitochondrial
outer membrane and MOMP, which is counteracted
through the sequestering of BAK by BCL-2. Small mole-
cules that disrupt this interaction (e.g. ABT-737 [51]) make
cells more susceptible to apoptosis and are thereby useful
in killing cancer cells that have become resistant to apo-
ptosis due to increased expression of BCL-2 [51].
Other promising mitochondrial targets for pharmaco-
logical intervention are the intimately linked processes of
mitochondrial fission, fusion and autophagy that allow
cells to respond to damage by either degrading damaged
mitochondria or by apoptosis [10]. The accumulation of
damaged and defective mitochondria decreases the pool of
correctly functioning mitochondria and increases the like-
lihood of cell death through disrupted mitochondria releas-
ing pro-apoptotic factors. This can occur with damaged
mitochondria acting as ATP consumers by reversal of the
ATP synthase and by increasing cellular oxidative stress.
Enhancing the clearance of damaged mitochondria would
allow the cell to replenish the pool of well-functioning
mitochondria and thereby normalize ATP supply and cal-
cium homeostasis. Therefore, the goal is to design small
molecules to manipulate these processes to eliminate dam-
aged mitochondria by upregulating autophagy. There are
also compounds that interact with the mitochondrial fis-
sion and fusion machinery, such as Mitochondrial Division
Inhibitor 1 (Mdivi-1) [59]. This compound inhibits dynamin
related protein-1 (DRP-1) which is required for mitochon-
drial fission and fragmentation [59]. Inhibition of mito-
chondrial fragmentation by Mdivi-1 decreases MOMP and
apoptotic cell death [59], as well as cell death after cardiac
Table 2. Potentially therapeutic compounds that affect mitochondriaa
In vivo
Compound Mode of action Potential indications
Cyclosporin A (CsA) Inhibits mPT I/R injury [52]; Bethlem myopathy and Ullrich
congenital muscular dystrophy [53]
Dichloroacetate (DCA) Activates pyruvate dehydrogenase complex Improved cardiac function [97]
Idebenone Bypasses blocks in complex I, antioxidant Neurodegeneration and cardiomyopathy [98]
Methylene blue Increases complex IV activity Alzheimer’s models [66]
2,4-Dinitrophenol (DNP) Uncoupler Obesity and elevated oxidative stress [61]
Bezafibrate Pan PPAR agonist elevating PGC-1a expression Increased mitochondrial biogenesis [70], but see [71]
AICAR AMPK agonist to increased mitochondrial biogenesis [71] Increases PGC-1a activity leading
CGP37157 Inhibits the mitochondrial Ca2+/Na+ exchanger Prevents mitochondrial calcium dyshomeostasis [99]
Mdivi-1 Inhibits dynamin related protein-1 (DRP-1) [59] Impacts on MOMP, apoptotic cell death
and cardiac I/R injury [60]
aOnly a representative sample of compounds that interact with mitochondria in potentially therapeutic ways is listed here.
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6I/R injury [60], thus modulating mitochondrial fragmenta-
tion has therapeutic potential. There are many other
putative drug targets within mitochondria that could be
selectively modified by small molecules, and a selection of
some of the most promising examples, chosen to illustrate
the range of systems and approaches that can be used to
affect mitochondrial function, is outlined in Table 2.
Several processes that are specific to mitochondria can
be targeted in less conventional ways with potential ther-
apeutic benefit. A good example is the proton leak through
the mitochondrial inner membrane [61]. Increasing the
rate of proton leak through the inner membrane has two
potential benefits: mitochondrial respiration will be less
efficient, thereby converting stored fat to heat [61], as
occurs during thermogenesis in brown adipose tissue mi-
tochondria through uncoupling protein 1; secondly, mild
uncoupling may reduce oxidative stress by decreasing the
level of the proton motive force and oxidizing electron
carrier pools such as those of dihydronicotinamide adenine
dinucleotide (NADH) and CoQ [61]. The mitochondrial
proton leak can be increased by the use of protonophores
or uncouplers that directly carry protons across the inner
membrane. The best example of this is DNP (Table 2),
which was found to cause weight loss in armaments work-
ers handling nitroaromatic compounds, and was subse-
quently used as a slimming agent in the 1930s [61].
However, the therapeutic window was fairly narrow lead-
ing to fatalities and its use has since been banned [61].
Nevertheless, DNP was very effective at promoting weight
loss so there have been several attempts to modify uncou-
plers so they can be used safely as treatments for chronic
obesity, for example by the development of self-limiting
uncouplers [62,63]. Alternatively, there has been a search
for factors that can accelerate proton leak by endogenous
protein pathways within mitochondria [63], but as yet none
of these have been found to be effective in vivo.
Another potential therapeutic approach for ameliorating
mitochondrial disorders is to bypass damaged sections of the
respiratory chain. For example, if a particular step in the
respiratory chain is defective due to an mtDNA mutation,
providing a pathway for electrons to bypass this respiratory
defect would enable proton pumping and ATP synthesis to
continue at the undamaged steps in the chain. Conversely,
facilitating the electron bypass of a proton pumping step in
normally functioning mitochondria might also be beneficial,as it would lead to less efficient ATP synthesis. This would
act similarly to mild uncoupling and decrease both oxidative
stress and fat accumulation. The efficacy of bypassing steps
in the respiratory chain in vivo has been demonstrated by
bypassing complex I through the overexpression of a yeast
nonproton pumping NADH dehydrogenase [64], and
through bypassing cytochrome oxidase in flies using an
alternative terminal oxidase [65]. The challenge for this
approach is to achieve these effects using a redox-active
small molecule to bypass a defective or normal proton
pumping step within mitochondria in vivo. The successful
compound would need to have appropriate reduction poten-
tials and reaction kinetics to transfer electrons and thereby
bypass one of the three proton pumping sites in the respira-
tory chain. One compound that has shown promise in this
regard within cells is methylene blue [66], which can pick up
electrons from various NAD(P)H dehydrogenases and then
donate electrons to cyt c. Its mode of action is unclear but a
major aspect may be to increase expression of complex IV,
perhaps as a response to the more reduced cyt c pool [66].
The therapeutic benefit of short chain ubiquinones such as
idebenone may at least in part be due to bypassing a defec-
tive or damaged complex I by picking up electrons in the
cytosol from the dicoumerol-sensitive NAD(P)H:quinone
oxidoreductase 1 and passing them on to complex III [67].
Finally, in a single patient study, treatment with ascorbate
and menadione to bypass a defect in complex III gave
evidence of both improved mitochondrial and muscle func-
tion [68]. Manipulating the pathway of electron flow through
the mitochondrial respiratory chain is therefore an inter-
esting therapeutic strategy, but the medicinal chemistry
challenges are significant.
Pharmacological agents that affect mitochondria
indirectly
A final strategy is to use small molecules to modulate
systems outside mitochondria that control the number
and activity of the organelle. Typically this involves manip-
ulating endogenous pathways that normally enable mito-
chondrial content and activity to respond to environmental
demands, such as increased workload or changes in nutrient
supply. This can be done by altering the transcription of
nuclear-encoded mitochondrial genes, and several path-
ways can be manipulated either directly or indirectly to
do this. The most extensively studied example is PGC-1a,349
Review Trends in Pharmacological Sciences June 2012, Vol. 33, No. 6the master regulator of mitochondrial biogenesis. PGC-1a
upregulates the activity of transcription factors that are
involved in mitochondrial biogenesis, such as Nuclear Re-
spiratory Factor (NRF)-1, which in turn modulates the
expression of other factors such as Transcription Factor
A, Mitochondrial (TFAM), which are important for mtDNA
replication and transcription [13]. The pharmacological
upregulation of PGC-1a activity may be a way of restoring
mitochondrial biogenesis to overcome a mitochondrial de-
fect or to respond to an increase in energy demand. The level
of PGC-1a expression is controlled by the activity of Peroxi-
some Proliferator-Activated Receptor (PPAR)g, and in the
shorter term its activity responds to AMPK which acts as a
cytosolic ATP/ADP sensor that responds to an energy deficit
via the phosphorylation of PGC-1a, which leads to its mi-
gration to the nucleus and activation of nuclear-encoded
mitochondrial genes. PGC-1a activity can also respond to
calcium/calmodulin-dependent protein kinase (CAMK) IV,
enabling its activity to respond to calcium signals such as
those involved in muscle contraction. PGC-1a is also affect-
ed by NO through cGMP levels and its activity can be
increased via acetylation [13,69]. The activity of PGC-1a
has been modified pharmacologically by upregulating its
expression through the use of the pan PPAR agonist, beza-
fibrate, which enabled a defect in a complex IV assembly
factor to be suppressed in a mouse model in vivo [70].
However, in a later study, bezafibrate was ineffective
against a similar complex IV assembly mutation; but in
this case, activating PGC-1a indirectly using the AMPK
agonist AICAR prevented the complex IV defect [71]. Thus,
the pharmacological manipulation of PGC-1a activity is a
particularly promising strategy as a therapy for mitochon-
drial disorders.
Several other closely integrated and overlapping path-
ways can upregulate mitochondrial activity by altering
transcription. Among these are the NAD+-dependent dea-
cetylases belonging to the sirtuin family [69]. For example,
the nuclear pool of Sirtuin3 can deacetylate and thereby
activate the forkhead transcription factor, FOXO3a, upre-
gulating the expression of mitochondrial antioxidant
enzymes such as MnSOD [72]. Changes in the acetylation
status of histones and of other transcription factors and
coactivators, such as PGC-1a, also affect the transcription
of mitochondrial genes, and this complicates the interpre-
tation of sirtuin activity on mitochondria. Nonetheless, the
suggestion that small molecule sirtuin activators based on
resveratrol have potential clinical applications has stimu-
lated interest in pharmacological manipulation of mito-
chondria through altering sirtuin activity [73–75].
However, at this time, the knowledge of the mechanism(s)
of their interactions with sirtuins is incomplete [76]. Even
so, the pharmacological manipulation of mitochondrial
function by small molecules acting on the endogenous
pathways that control the expression of mitochondrial
genes and thereby enable organelle function to match
demand and respond to damage is a very appealing strat-
egy for mitochondrial pharmacology.
Concluding remarks
In this review, we have focused on the general principles
associated with the emerging field of mitochondrial350pharmacology. To date, mitochondria have been a neglected
drug target but show tremendous clinical potential. Of
particular importance is the realization that secondary
mitochondrial damage contributes to a wide range of dis-
orders and that there are a few core aspects of mitochondrial
pathology that frequently arise in many disparate diseases.
This implies that therapies designed to interact with these
core features can be applied to many diverse and prevalent
medical disorders. One common aspect to mitochondrial
pathology, elevated oxidative stress, can be treated by mi-
tochondria-targeted antioxidants and these have proven
effective across a broad spectrum of diseases. Although
we have focused on therapeutic interventions to human
mitochondria, the principles outlined here can be applied
to many other situations, for example in veterinary medi-
cine or in developing new ways of targeting parasites.
Several challenges will need to be recognized and over-
come for mitochondrial pharmacology to achieve its full
potential. One is the development of biomarkers and mea-
surements of mitochondrial function in vivo to ascertain if
the therapy is actually affecting mitochondria. Currently,
many clinical trials are inconclusive in this regard. Often,
it is unclear whether the outcome was mediated through a
change in mitochondrial function or, conversely, if mito-
chondrial function was indeed altered but did not have a
clinical impact. Biomarkers for whole body oxidative stress
such as isoprostanes for lipid peroxidation have been
developed, but their relationship to mitochondrial damage
is not well substantiated. Methods are being developed to
directly assess mitochondrial ROS production and oxida-
tive damage in whole animals [77,78]. Mitochondrial func-
tion is also being assessed in real time in vivo by the
development of mitochondria-targeted PET probes [79]
and by the use of 31P-MRI to assess ATP synthesis, al-
though its effectiveness in clinical trials is limited [80]. It is
clear that new and better ways to assess all aspects of
mitochondrial function within patients is essential for the
future development of mitochondrial pharmacology. To
conclude, mitochondrial pharmacology is an emerging dis-
cipline of great promise and potential for new therapeutic
approaches with implications for most aspects of medicine.
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